Skip to content
Inciteful Med

Biology, Genetics & Subtypes of Fabry Disease

Last updated:

Fabry disease is caused by a mutation in the GLA gene that prevents the body from breaking down a fatty waste called Gb3. Because it is an X-linked genetic disorder, inheritance patterns depend on which parent has the gene, and females can experience symptoms just as severe as males.

Key Takeaways

  • • Fabry disease is caused by a GLA gene mutation that creates a deficiency in the alpha-galactosidase A enzyme.
  • • The classic phenotype typically starts in childhood, while the late-onset phenotype often appears in adulthood and primarily affects the heart.
  • • Because Fabry disease is X-linked, a father passes the gene to all of his daughters but none of his sons.
  • • Females with the gene are not simply asymptomatic carriers and can develop severe symptoms due to X-chromosome inactivation.
  • • Genetic sequencing, rather than standard enzyme blood testing, is the only reliable way to diagnose Fabry disease in females.

To understand Fabry disease, it helps to look at the body’s cellular “recycling” system. At its core, this is a condition where a specific genetic instruction is incorrect, causing a ripple effect that touches almost every organ system in the body [1][2].

The Biological Mechanism

The root cause of Fabry disease is a mutation (a “misspelling”) in the GLA gene [3][1]. This gene provides the instructions for making an enzyme called alpha-galactosidase A (α\alpha-Gal A) [3][2].

In a healthy body, this enzyme lives inside the lysosome (the cell’s recycling center) and breaks down a fatty substance called globotriaosylceramide (Gb3) [1][2]. When the enzyme is missing or faulty:

  1. Gb3 Accumulates: The fatty waste (Gb3) cannot be broken down and starts to pile up inside cells [3][1].
  2. Lyso-Gb3 Forms: A related, toxic substance called Lyso-Gb3 also builds up in the blood [3][4].
  3. Cellular Damage: Over time, this buildup causes inflammation and scarring in the blood vessels, heart, kidneys, and nervous system [3][5].

Classic vs. Late-Onset Phenotypes

Doctors generally group Fabry disease into two “phenotypes” (how the disease shows up) based on how much enzyme activity is left in the body [6].

  • Classic Phenotype: Usually seen in males with little to no enzyme activity (less than 1% of normal) [7][8]. Symptoms typically begin in childhood or the teenage years and include burning hand/foot pain, lack of sweating, and skin spots (angiokeratomas) [7][3].
  • Late-Onset (Non-Classic) Phenotype: These individuals have some residual enzyme activity (often between 1% and 30%) [9][7]. Symptoms may not appear until the 30s to 70s and often focus on a single organ, most commonly the heart (causing thickening of the heart muscle) [9][10].

The X-Linked Factor

Fabry disease is an X-linked disorder, meaning the GLA gene is located on the X chromosome [3][11]. Because males have only one X chromosome, if that X has the Fabry mutation, they will develop the disease [1][12].

Females have two X chromosomes. For a long time, medical textbooks incorrectly described females as “asymptomatic carriers”—people who carry the gene but don’t get sick. We now know this is wrong. Many females experience symptoms ranging from mild to just as severe as those seen in males [11][13][14].

Why Females are Not “Just Carriers”

The reason females have such variable symptoms is a process called X-chromosome inactivation (Lyonization) [1][11].

  • Early in development, every cell in a female’s body randomly “turns off” one of its two X chromosomes [1][11].
  • This creates a “mosaic” effect: some cells use the healthy X chromosome and produce the enzyme, while other cells use the Fabry X chromosome and do not [1][11].
  • If a woman’s body randomly turns off more of the “healthy” X chromosomes in her heart or kidneys, she may develop severe disease in those organs [11][15].

Because of this mosaic effect, a woman’s blood test for enzyme levels can appear completely “normal” even if she has significant disease in her organs [14][16]. For this reason, genetic sequencing of the GLA gene is the only reliable way to diagnose Fabry disease in females [14][17].

Passing It On: Inheritance Rules

Because the GLA gene is on the X chromosome, the rules for passing it to your children are very specific [3]:

  • If the father has Fabry: He will pass the gene to 100% of his daughters (they will inherit his X chromosome). He will pass it to 0% of his sons (they inherit his Y chromosome) [11][12].
  • If the mother has Fabry: She has a 50% chance of passing the gene to any child, whether male or female, with each pregnancy [11][12].
    Understanding these rules is crucial for family planning, and genetic counselors can help you navigate reproductive options [18].

Frequently Asked Questions

What is the GLA gene mutation in Fabry disease?
The GLA gene provides the instructions for making the alpha-galactosidase A enzyme, which helps clear fatty waste from your cells. A mutation in this gene means the enzyme doesn't work properly, causing a toxic buildup of waste that damages organs over time.
What is the difference between classic and late-onset Fabry disease?
Classic Fabry disease usually begins in childhood with severe symptoms like burning pain and lack of sweating due to having almost no enzyme activity. Late-onset Fabry disease appears later in life, often in the 30s to 70s, and typically affects a single organ like the heart.
Why are females with Fabry disease not just carriers?
Females with the Fabry gene can develop mild to severe symptoms due to a process called X-chromosome inactivation. Because some cells use the healthy X chromosome while others use the mutated one, organs like the heart or kidneys can still suffer significant damage.
Why is a normal enzyme test not enough to rule out Fabry disease in females?
Because a female's body randomly turns off one of its two X chromosomes in each cell, a standard blood test might show normal overall enzyme levels even if her organs are being damaged. Genetic sequencing of the GLA gene is the only reliable way to officially diagnose females.
How is Fabry disease passed down from parents to children?
Fabry disease is an X-linked condition. A father with the gene will pass it to all of his daughters but none of his sons. A mother with the gene has a 50 percent chance of passing it to any of her children, regardless of their sex.

Questions for Your Doctor

  • • What is the specific mutation in my/my child's GLA gene, and is it associated with the 'classic' or 'late-onset' phenotype?
  • • What was the measured alpha-galactosidase A enzyme activity, and what does that mean for our treatment plan?
  • • For the females in our family, can we rely on enzyme testing, or is GLA gene sequencing the only way to be sure?
  • • Is my/my child's mutation 'amenable' to oral chaperone therapy (migalastat), or is IV enzyme replacement therapy (ERT) the standard?
  • • Based on the mutation, what specific organs (heart, kidneys, etc.) should we be monitoring most closely?

Questions for You

  • • If I am female, what symptoms am I experiencing? Have I been told I was 'just a carrier' in the past?
  • • Has my doctor ordered a Lyso-Gb3 blood test to help monitor how much waste is building up in my cells?
  • • Which male and female relatives should I share this genetic information with, given how X-linked inheritance works?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations.

    Izhar R, Borriello M, La Russa A, et al.

    Genes 2023; (15(1)) doi:10.3390/genes15010037.

    PMID: 38254927
  2. 2

    [The neurological manifestations of Fabry disease. A review].

    Firsov KV, Kotov AS

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2016; (116(9)):98-105 doi:10.17116/jnevro20161169198-105.

    PMID: 27735906
  3. 3

    Treatment of Anderson-Fabry Disease.

    Simonetta I, Tuttolomondo A, Daidone M, et al.

    Current pharmaceutical design 2020; (26(40)):5089-5099 doi:10.2174/1381612826666200317142412.

    PMID: 32183665
  4. 4

    The importance of a multidisciplinary approach in two tricky cases: the perfect match for Fabry disease.

    Berti GM, Aiello V, Vischini G, et al.

    BMC nephrology 2025; (26(1)):77 doi:10.1186/s12882-025-04009-2.

    PMID: 39948544
  5. 5

    Anderson-Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement.

    Iorio A, Lucà F, Pozzi A, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(2)) doi:10.3390/diagnostics14020208.

    PMID: 38248084
  6. 6

    An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease.

    Germain DP, Altarescu G, Barriales-Villa R, et al.

    Molecular genetics and metabolism 2022; (137(1-2)):49-61 doi:10.1016/j.ymgme.2022.07.010.

    PMID: 35926321
  7. 7

    When and How to Diagnose Fabry Disease in Clinical Pratice.

    Michaud M, Mauhin W, Belmatoug N, et al.

    The American journal of the medical sciences 2020; (360(6)):641-649 doi:10.1016/j.amjms.2020.07.011.

    PMID: 32723516
  8. 8

    Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.

    Maruyama H, Miyata K, Mikame M, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(1)):44-52 doi:10.1038/gim.2018.31.

    PMID: 29543226
  9. 9

    Late-Onset Fabry Disease Affecting the Kidneys and Liver While Sparing the Heart: A Case Report.

    Alitter Q

    Cureus 2022; (14(11)):e30989 doi:10.7759/cureus.30989.

    PMID: 36475199
  10. 10

    [Fabry disease: A review].

    Michaud M, Mauhin W, Belmatoug N, et al.

    La Revue de medecine interne 2021; (42(2)):110-119 doi:10.1016/j.revmed.2020.08.019.

    PMID: 33172708
  11. 11

    Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report.

    Rodríguez Doyágüez P, Furlano M, Ars Criach E, et al.

    Nefrologia 2023; (43 Suppl 2()):91-95 doi:10.1016/j.nefroe.2024.01.018.

    PMID: 38278716
  12. 12

    [Guidelines for diagnosis, therapy and follow up of Anderson-Fabry disease].

    Kes VB, Cesarik M, Zavoreo I, et al.

    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 2014; (68(2)):223-32.

    PMID: 26012164
  13. 13

    Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease.

    Tuttolomondo A, Simonetta I, Duro G, et al.

    Oncotarget 2017; (8(37)):61415-61424 doi:10.18632/oncotarget.18250.

    PMID: 28977874
  14. 14

    Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients.

    Duro G, Anania M, Zizzo C, et al.

    International journal of molecular sciences 2024; (25(10)) doi:10.3390/ijms25105158.

    PMID: 38791200
  15. 15

    Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLA gene.

    Hossain MA, Wu C, Yanagisawa H, et al.

    Molecular genetics and metabolism reports 2019; (20()):100497 doi:10.1016/j.ymgmr.2019.100497.

    PMID: 31372342
  16. 16

    X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis.

    Viggiano E, Politano L

    International journal of molecular sciences 2021; (22(14)) doi:10.3390/ijms22147663.

    PMID: 34299283
  17. 17

    Case report: is low α-Gal enzyme activity sufficient to establish the diagnosis of Fabry disease?

    Biagini G, Almeida ACSF, Almeida TVR, et al.

    Jornal brasileiro de nefrologia 2017; (39(3)):333-336 doi:10.5935/0101-2800.20170057.

    PMID: 29044343
  18. 18

    The unlikely combination: Anderson-Fabry disease and congenital dyserythropoietic anemia type II in a pediatric patient.

    Elsherif Y, Ibrahim IA, Elsherif O, Abukhadijah HJ

    Clinical case reports 2024; (12(10)):e9354 doi:10.1002/ccr3.9354.

    PMID: 39386347

This page explains the genetics and biology of Fabry disease for educational purposes. Always consult a genetic counselor or healthcare provider to understand how this information applies to your family's specific situation.

Stay up to date

Get notified when new research about Fabry disease is published.

No spam. Unsubscribe anytime.